Pluri Inc (PLUR) USD0.00001

Sell:$4.69Buy:$6.14$0.55 (9.00%)

Prices delayed by at least 15 minutes
Sell:$4.69
Buy:$6.14
Change:$0.55 (9.00%)
Prices delayed by at least 15 minutes
Sell:$4.69
Buy:$6.14
Change:$0.55 (9.00%)
Prices delayed by at least 15 minutes

Company Information

About this company

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.

Key people

Zalman Aberman
Chairman of the Board
Yaky Yanay
President, Chief Executive Officer, Director
Liat Zalts
Chief Financial Officer, Treasurer
Lorne Abony
Director
Alejandro Weinstein M.
Non-Executive Director
Doron Birger
Independent Director
Rami Levi
Independent Director
Maital Shemesh-Rasmussen
Independent Director
Click to see more

Key facts

  • EPIC
    PLUR
  • Location
    Israel
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US72942G2030
  • Market cap
    $47.23m
  • Employees
    106
  • Shares in issue
    7.00m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.